Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases
- Broad multiyear alliance with
Columbia University Irving Medical Centerresearchers to focus on development of potential medicines using genetic based therapies and create a therapeutic platform for a range of rare neurological conditions Ovidto collaborate with renowned clinical and molecular geneticist expert, Wendy K. Chung, M.D., Ph.D.
- Collaboration provides
Ovidwith the opportunity to expand future drug development portfolio
Under this research and translational development alliance, Columbia will align its expertise in rare disease genetics and deep clinical understanding of rare neurological diseases with Ovid’s discovery, translational, and clinical development expertise in neurodevelopmental disorders and rare epilepsies.
Under the collaboration,
“Ovid has made significant progress in all its late stage clinical programs. We are excited to see multiple read outs of clinical data throughout the year. It’s time to begin to build our pipeline for our long-term future in a disciplined and strategic fashion. This next step is built on, and will complement, the important programs we already have in place,” said
“My laboratory is committed to discovering innovative new targets and therapies to address rare neurological diseases with few or no treatment options,” said
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding: advancing and commercializing Ovid’s product candidates, progress, timing, scope and the development and potential benefits of Ovid’s product candidates; and the anticipated reporting schedule of clinical data regarding Ovid’s product candidates. You can identify forward-looking statements because they contain words such as “will,” “appears,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Investors and Media:
Investor Relations & Public Relations
Source: Ovid Therapeutics Inc.